Chief Medical Officer
Deya Corzo, M.D., is an expert in biotechnology drug development, genetics and rare diseases with nearly two decades of experience leading clinical research initiatives.
Previously, Dr. Corzo served as Chief Medical Officer of Sojournix Inc., a privately held company in the women’s health space, where she was responsible for leading the build-out of the company’s clinical research organization.
Dr. Corzo previously served as SVP of R&D and Therapeutic Area Head for liver-amenable gene therapies at uniQure. In that role she led efforts to develop a portfolio of preclinical AAV-based programs and she oversaw a proof-of-concept clinical trial in hemophilia B for a gene therapy product that obtained Breakthrough Therapy and PRIME designation.
Dr. Corzo launched her biotechnology career at Genzyme where she led the medical team responsible for the global registration of Myozyme and Lumizyme, the only approved enzyme replacement therapies for Pompe disease.
Dr. Corzo is a faculty member of Harvard Medical School and a board-certified attending physician in Clinical Genetics at Boston Children’s Hospital. She completed a residency in Pediatrics at Maimonides Medical Center in Brooklyn, NY, and a clinical fellowship in Genetics at Boston Children’s Hospital. Dr. Corzo received her medical degree from the Universidad Industrial de Santander in her native Colombia.